Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab-Reference-Cited by-同舟云学术

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

Published:2013-02-20 Issue:3 Volume:7 Page:580-594
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:

Author:

Mamidi Srinivas,Cinci Marc,Hasmann Max,Fehring Volker,Kirschfink Michael

Funder

BMBF BIODISC

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference59 articles.

1. RNAi therapeutics: principles, prospects and challenges;Aagaard;Adv. Drug Deliv. Rev.,2007

2. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression;Aleku;Cancer Res.,2008

3. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance;Barok;Mol. Cancer Ther.,2007

4. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N. Engl. J. Med.,2012

5. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy;Bellone;Br. J. Cancer,2012

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab;International Journal of Molecular Sciences;2024-08-01

2. New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?;Cancers;2024-07-05

3. Lipoplexes’ Structure, Preparation, and Role in Managing Different Diseases;AAPS PharmSciTech;2024-06-07

4. Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology;Regulatory Mechanisms in Biosystems;2024-05-11

5. Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways;International Journal of Molecular Sciences;2024-04-07